Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target
I'm PortAI, I can summarize articles.
Debanjana Chatterjee from JonesTrading has maintained a Buy rating on Sagimet Biosciences, Inc. Class A, with a price target of $26. The rating is supported by the company's advancing pipeline, strong clinical momentum, and strategic positioning. Key factors include favorable Phase 1 data for deni-resmetirom, upcoming regulatory interactions, and the potential of FASN inhibitors in various indications. Chatterjee also highlights the competitive acne data and the long-term development pathway strengthened by the TAPI licensing agreement, reinforcing confidence in the company's execution and growth prospects.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments